-transparent.png){kind=logo}
A randomized double-blind study with a 3-yr follow-up comparing the two arms "orchiectomy + Anandron (300 mg)" vs "orchiectomy + placebo" in 125 patients with stage D prostate cancer has confirmed the beneficial effects of the combined Anandron therapy on subjective parameters and on the best objective response (NPCP criteria), although these effects were not statistically significant, but failed to detect any improvement in time-to-disease progression or survival. Comparison with the results of other trials emphasizes the urgent need to establish suitable prognostic factors by further clinical research before evaluating the benefits of individual drugs.
Related Publications
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
January 1991,
Urology,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
December 1993,
Cancer,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
January 1995,
European urology,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
August 1986,
American journal of clinical oncology,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
January 1987,
Progress in clinical and biological research,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
August 1989,
Helvetica chirurgica acta,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
December 1993,
Cancer,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
January 1993,
International surgery,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
October 1992,
The Journal of urology,
M Namer, and
J Toubol, and
A Caty, and
J E Couette, and
J Douchez, and
P Kerbrat, and
J P Droz
January 1984,
Journal of surgical oncology,
